Related Experiment Video

Updated: Aug 22, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

New approaches for antithrombotic antiplatelet therapies

H Ulrichts1, K Vanhoorelbeke, G Van De Walle

  • 1Laboratory for Thrombosis Research, KULeuven campus Kortrijk, Kortrijk, Belgium. Hans.Ulrichts@kulak.ac.be

Current Medicinal Chemistry
|September 24, 2004
PubMed

Insights

New antiplatelet compounds are being developed to improve cardiovascular disease treatment. This review discusses novel compounds targeting platelet function and their safety assessment using bleeding time tests and models.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Thrombosis Research

Background:

  • Cardiovascular diseases are a leading cause of mortality.
  • Platelet-dependent thrombosis is central to cardiovascular disease pathophysiology.
  • Current antiplatelet strategies have limitations in efficacy and safety.

Purpose of the Study:

  • To review novel antiplatelet compounds with demonstrated in vivo antithrombotic action.
  • To discuss the targets and potential applications of these new compounds.
  • To evaluate the utility of bleeding time tests and bleeding models for assessing the safety of novel antiplatelet agents.

Main Methods:

  • Literature review of novel antiplatelet compounds.
  • Analysis of studies demonstrating in vivo antithrombotic effects.
  • Evaluation of bleeding time tests and bleeding models for safety prediction.

Main Results:

  • Several novel antiplatelet compounds targeting specific platelet functions are under development.
  • Evidence supports the in vivo antithrombotic action of these compounds.
  • Bleeding time tests and bleeding models are crucial for predicting the safety profile of new antiplatelet agents.

Conclusions:

  • Novel antiplatelet compounds offer potential for improved cardiovascular disease management.
  • Careful safety assessment using established tests is essential for clinical translation.
  • Further research is needed to optimize the efficacy and safety of these agents.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...